Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + fluzoparib in metastatic castration-resistant prostate cancer after progression on novel endocrine therapy
ChiCTR2100043664Phase 4Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and fluzoparib in prostate cancer (PCa), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: response rate. Started Apr 2021; status: recruiting.
02
Drugs
camrelizumabfluzoparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2100043664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043664.